Holen Sie sich die Stockscreener-App
4.14
0.73%
0.03
Schlusskurs vom Vortag:
$4.11
Offen:
$4.2
24-Stunden-Volumen:
1.84M
Relative Volume:
1.82
Marktkapitalisierung:
$159.23M
Einnahmen:
$210.70K
Nettoeinkommen (Verlust:
$-21.37M
KGV:
-3.7636
EPS:
-1.1
Netto-Cashflow:
$-21.10M
1W Leistung:
+7.53%
1M Leistung:
+40.34%
6M Leistung:
+130.00%
1J Leistung:
+147.90%
1-Tages-Spanne:
$4.03
$4.30
1-Wochen-Bereich:
$3.60
$4.34
52-Wochen-Spanne:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Firmenname
Gain Therapeutics Inc
Sektor
Branche
Telefon
(301) 500-1556
Adresse
4800 HAMPDEN LANE, BETHESDA
Vergleichen Sie GANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
4.14 | 158.08M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-08-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-12 | Eingeleitet | BTIG Research | Buy |
| 2021-04-12 | Eingeleitet | Oppenheimer | Outperform |
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn
AI and Physics-Based Modeling Identifies a New Parkinson’s Disease Drug - the-scientist.com
Gain Therapeutics At A Crossroads: Will GT-02287 Deliver Disease-Modifying Proof? - RTTNews
How sustainable is Gain Therapeutics Inc stock dividend payoutProfit Target & Consistent Growth Equity Picks - moha.gov.vn
Gain Therapeutics Inc (GANX) expanding its growth trajectory ahead - setenews.com
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy - Yahoo Finance
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Winners Losers: Is Gain Therapeutics Inc stock a smart buy before Fed meeting2025 Volume Leaders & Fast Momentum Stock Entry Tips - moha.gov.vn
Gain Therapeutics Announces New Stock Offering Program - MSN
Gain Therapeutics, Inc. (GANX) 5.14% in After-hours: What’s Driving the Move? - Stocks Telegraph
Levels Update: Will Repare Therapeutics Inc. stock gain from lower inflation2025 AllTime Highs & Expert Verified Movement Alerts - moha.gov.vn
FY2025 Earnings Forecast for GANX Issued By HC Wainwright - MarketBeat
HC Wainwright Predicts Higher Earnings for Gain Therapeutics - Defense World
H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data By Investing.com - Investing.com South Africa
Gain Therapeutics (GANX) Stock Analysis Report | Financials & Insights - Benzinga
H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data - Investing.com Canada
Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development - MSN
What drives Gain Therapeutics Inc stock priceGrowth vs. Value Investing & Low Cost Market Strategies - earlytimes.in
Gain Therapeutics files prospectus supplement for $35.5 million stock offering By Investing.com - Investing.com Australia
Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development - Finviz
Gain Therapeutics files prospectus supplement for $35.5 million stock offering - Investing.com
Gain Therapeutics files prospectus for $35.5 million stock saleSEC filing - marketscreener.com
Gain Therapeutics Files Prospectus Supplement for Stock Offering - TradingView
Can Gain Therapeutics Inc. stock sustain institutional interestTrend Reversal & Smart Allocation Stock Reports - moha.gov.vn
12 Hot Penny Stocks to Invest in Right Now - Insider Monkey
Valuation Update: Why Gain Therapeutics Inc. stock could see breakout soonNew Guidance & Daily Technical Stock Forecast Reports - moha.gov.vn
Will Coeptis Therapeutics Holdings Inc. stock gain from government policiesJuly 2025 Update & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
A History of Outperforming Analyst Forecasts and Beating the Odds: Gain Therapeutics Inc (GANX) - setenews.com
Gain Therapeutics Inc Stock Analysis and ForecastRisk-Reward Ratio Analysis & Rapid Wealth Building Tips - earlytimes.in
How Gain Therapeutics Inc. stock compares to industry benchmarksWeekly Profit Report & Expert Approved Trade Ideas - newser.com
Gain Therapeutics presents data on GT-02287 - TipRanks
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - The Manila Times
Gain Therapeutics (Nasdaq: GANX) Reports GT-02287 Mitochondrial, Neuronal Data - Stock Titan
Will Gain Therapeutics Inc. stock deliver strong dividend growthInsider Buying & Real-Time Volume Analysis Alerts - newser.com
Gain Therapeutics Inc. stock outlook for YEARJuly 2025 Short Interest & Risk Controlled Swing Alerts - newser.com
Is Gain Therapeutics Inc. stock ready for a breakoutWeekly Trade Recap & Weekly Breakout Watchlists - newser.com
Can machine learning forecast Gain Therapeutics Inc. recovery2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know - sharewise.com
How does Gain Therapeutics Inc (GANX) change from a tortoise to a hare? - Setenews
Is Gain Therapeutics Inc. stock undervalued vs historical averagesQuarterly Market Summary & Consistent Growth Stock Picks - newser.com
Equities Analysts Set Expectations for GANX FY2025 Earnings - Defense World
Will Gain Therapeutics Inc. stock go up soon2025 Price Targets & AI Enhanced Trading Signals - newser.com
Finanzdaten der Gain Therapeutics Inc-Aktie (GANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):